Electronic Trial Master File Systems Market - Global Forecast To 2030
商品番号 : SMB-90648
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年10月 |
| ページ数 | 337 |
| 図表数 | 415 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
電子トライアルマスターファイル（eTMF）システム市場 – 製品（統合型、スタンドアロン型）、機能（分析、コンプライアンス、ワークフロー、監査）、治療（腫瘍、心臓、神経）、エンドユーザー（製薬、バイオテクノロジー、医療機器）、フェーズ、地域別 – 2030年までの世界予測
世界の電子トライアルマスターファイル（eTMF）システム市場は、2025年の13億6,000万米ドルから2030年には24億9,000万米ドルに達し、予測期間中に12.8%の高いCAGRで成長すると予測されています。臨床試験管理の合理化、規制遵守、データ整合性に対する需要の高まりを背景に、市場は着実に成長しています。デジタルおよびクラウドベースのソリューションの導入拡大に加え、リアルタイムの文書追跡、自動レポート作成、試験実施施設間の連携強化へのニーズが高まり、成長を後押ししています。効率性の向上に焦点を当てたFrost & Sullivan（2024年）の最近の調査では、eTMFシステムによって監査および試験実施施設の準備にかかる時間が最大30%短縮され、医薬品承認プロセスが加速すると推定されています。さらに、製薬およびバイオテクノロジー研究への投資増加と、世界的な臨床試験の複雑化が相まって、世界中でeTMFシステムの導入が加速しています。
本レポートは、eTMFシステム市場を分析し、提供内容、機能、導入、治療領域、試験段階、エンドユーザー、地域に基づいて、様々な市場セグメントの市場規模と将来の成長可能性を推定することを目的としています。また、この市場で活動する主要企業の競合分析に加え、各社の企業概要、製品ラインナップ、最近の動向、主要な市場戦略についても提供しています。
このレポートは、既存企業だけでなく、新規参入企業や中小企業にとっても、市場の動向を把握し、市場シェアの拡大に役立てることができます。レポートを購入した企業は、以下の戦略のいずれか、または組み合わせて活用することで、市場での地位を強化できます。
本レポートでは、以下の点について洞察を提供します。
電子トライアルマスターファイル（eTMF）システム市場の成長に影響を与える主要な推進要因（臨床試験件数の増加、規制遵守と査察への対応、リアルタイムのデータ管理と分析、分散型およびグローバルな試験のサポート、クラウドベースおよび自動化ソリューションの導入）、制約要因（高額な導入・ライセンス費用、従来の紙ベースのシステムからの変更への抵抗）、機会（AIを活用した自動化とリスクベースの文書管理、コンプライアンスとリスク管理のための予測分析）、課題（データセキュリティとサイバーセキュリティのリスク、レガシーシステムとの相互運用性の問題）の分析
- 製品開発／イノベーション：電子トライアルマスターファイル（eTMF）システム市場における今後の技術、研究開発活動、新製品・サービス投入に関する詳細な洞察
- 市場開発：収益性の高い新興市場、提供内容、機能、導入、治療領域、試験段階、エンドユーザー、地域に関する包括的な情報
- 市場多様化：eTMFシステム市場における製品ポートフォリオ、成長地域、最近の開発状況、投資に関する網羅的な情報
- 競合評価：eTMFシステム市場における主要企業（Veeva Systems（米国）、Oracle（米国）、IQVIA（米国）、Medidata（米国）、Transperfect（米国）など）の市場シェア、成長戦略、製品提供、および能力に関する詳細な評価
Report Description
The global eTMF systems market is projected to reach USD 2.49 billion by 2030, up from USD 1.36 billion in 2025, at a high CAGR of 12.8% during the forecast period. The market is progressing steadily, driven by the growing demand for streamlined clinical trial management, regulatory compliance, and data integrity. The increasing adoption of digital and cloud-based solutions, coupled with the need for real-time document tracking, automated reporting, and enhanced collaboration across study sites, is fueling growth. Highlighting efficiency benefits, a recent Frost & Sullivan (2024) study estimates that eTMF systems can reduce audit and site preparation time by up to 30%, accelerating drug approval processes. Moreover, rising investments in pharmaceutical and biotechnology research, along with the complexity of global clinical trials, are accelerating the adoption of eTMF systems worldwide.
“The cloud-based segment, under the eTMF systems market, is the largest segment during the forecast period.”
Based on deployment, the cloud-based segment accounted for the largest share of the eTMF systems market, driven by the growing preference for scalable, secure, and accessible clinical trial management solutions. Cloud-based eTMF systems enable real-time document access, centralized collaboration across multiple study sites, and seamless integration with other digital health platforms. These solutions reduce IT infrastructure costs, simplify system maintenance, and ensure compliance with regulatory requirements through automated updates and audit-ready documentation. The increasing complexity of clinical trials, coupled with the need for remote monitoring and efficient data management, is driving the global adoption of cloud-based eTMF systems among pharmaceutical, biotechnology, and contract research organizations.
“Based on the end user, the contract research organizations (CROs) segment is expected to register the fastest growth during the forecast period.”
In 2024, based on end user, the contract research organizations (CROs) segment is expected to register the fastest growth in the eTMF systems market during the forecast period. The rising number of outsourced clinical trials and increasing complexity of study protocols are driving CROs to adopt eTMF systems for efficient and compliant document management. These systems enable the real-time tracking of trial documents, streamline workflows, and enhance collaboration across multiple study sites. Moreover, CROs benefit from enhanced data integrity, audit readiness, and regulatory compliance offered by eTMF solutions. Growing demand for faster trial execution and cost-effective operations is further fueling the rapid adoption of eTMF systems by CROs globally.
“Asia Pacific to witness the highest growth rate during the forecast period.”
Asia Pacific is expected to witness the highest growth rate in the eTMF systems market during the forecast period, driven by the rapid expansion of the pharmaceutical and biotechnology sectors across the region. Increasing clinical trial activities, rising outsourcing of trials to Contract Research Organizations (CROs), and growing adoption of digital solutions for efficient trial management are key factors fueling market growth. Moreover, improvements in healthcare infrastructure, favorable government initiatives, and rising investment in clinical research are supporting the adoption of advanced eTMF systems. Cloud-based platforms, analytics, and reporting functionalities are being increasingly implemented to ensure compliance, streamline workflows, and enhance data integrity. The combination of these factors positions the Asia Pacific as the fastest-growing regional market globally.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace. The breakdown of primary participants is as mentioned below:
- By Company Type – Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
- By Designation – Directors: 15%, Managers: 10%, and Others: 75%
- By Region – North America: 39%, Europe: 31%, Asia Pacific: 21, Latin America: 6%, Middle East & Africa: 3%
Key Players in the Market
The key players operating in the eTMF systems market include Veeva Systems (US), Oracle (US), IQVIA (US), Medidata (Dassault Systèmes) (US), TransPerfect (US), Phlexglobal (Cencora, Inc.) (UK), ArisGlobal (US), MasterControl Solutions, Inc. (US), Ennov (UK), Montrium Inc. (Canada), SureClinical Inc. (US), Florence Healthcare (US), Egnyte, Inc. (US), Cloudbyz (US), myClin Clinial Research LLC. (US), Octalsoft (US), Crucial Data Solutions (US), DataRiver S.r.l. (Italy), EXTEDO (Bertelsmann SE & Co. KGaA) (Germany), Aurea, Inc. (US), Agatha Inc. (Japan), EvidentIQ (Germany), Clinion (US), Anju Software Inc. (US), Clinevo Technologies (US).
Research Coverage:
The report analyzes the eTMF systems market, aiming to estimate the market size and future growth potential of various market segments based on offering, functionality, deployment, therapeutic area, trial phase, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report can use one or a combination of the following strategies to strengthen their market positions.
This report provides insights into:
- Analysis of key drivers (rising number of clinical trials, regulatory compliance and inspection readiness, real-time data management and analysis, support for decentralized and global trials, adoption of cloud-based and automated solutions), restraints (high setup and licensing costs, resistance to change from traditional paper-based systems), opportunities (AI-driven automation & risk-based document management, predictive analytics for compliance & risk management), and challenges (data security & cybersecurity risks, interoperability issues with legacy systems) influencing the growth of the eTMF systems market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the eTMF systems market
- Market Development: Comprehensive information on the lucrative emerging markets, offering, functionality, deployment, therapeutic area, trial phase, end user, and region
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the eTMF systems market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the eTMF systems market, like Veeva Systems (US), Oracle (US), IQVIA (US), Medidata (US), and Transperfect (US)
Table of Contents
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 33
1.3.2 INCLUSIONS AND EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 35
1.4 CURRENCY CONSIDERED 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH APPROACH 37
2.1.1 SECONDARY RESEARCH 38
2.1.1.1 Key data from secondary sources 39
2.1.2 PRIMARY RESEARCH 39
2.1.2.1 Primary sources 40
2.1.2.2 Key data from primary sources 41
2.1.2.3 Breakdown of primaries 41
2.1.2.4 Insights from primary experts 42
2.2 RESEARCH METHODOLOGY DESIGN 42
2.3 MARKET SIZE ESTIMATION 43
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.5 MARKET SHARE ESTIMATION 47
2.6 RESEARCH ASSUMPTIONS 48
2.7 RESEARCH LIMITATIONS 48
2.8 RISK ASSESSMENT 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 55
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 55
4.2 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING AND REGION 56
4.3 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57
4.4 REGIONAL MIX: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
(2023–2030) 57
4.5 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: DEVELOPED VS. EMERGING ECONOMIES, 2025 VS. 2030 (USD MILLION) 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
5.2.1 DRIVERS 60
5.2.1.1 Rising number of clinical trials 60
5.2.1.2 Growing regulatory scrutiny and need for inspection readiness 61
5.2.1.3 Increasing complexity of clinical trials 62
5.2.1.4 Growing shift toward decentralized and global clinical trial methodologies 62
5.2.1.5 Increasing adoption of cloud-based and automated solutions 63
5.2.2 RESTRAINTS 63
5.2.2.1 High setup and licensing costs 63
5.2.2.2 Resistance to change from traditional paper-based systems 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Integration of artificial intelligence and risk-based approaches 64
5.2.3.2 Predictive analytics for compliance & risk management 65
5.2.4 CHALLENGES 65
5.2.4.1 Data security & cybersecurity risks 65
5.2.4.2 Interoperability challenges with legacy systems 67
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 67
5.4 INDUSTRY TRENDS 68
5.4.1 SHIFT FROM PAPER-BASED TO DIGITAL TRIAL DOCUMENTATION 68
5.4.2 ADOPTION OF CLOUD-BASED AND SCALABLE SOLUTIONS 69
5.4.3 INTEGRATION WITH OTHER CLINICAL SYSTEMS 69
5.4.4 USE OF ARTIFICIAL INTELLIGENCE AND AUTOMATION 69
5.4.5 FOCUS ON REGULATORY COMPLIANCE AND INSPECTION READINESS 69
5.5 REGULATORY LANDSCAPE 69
5.5.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
5.5.2 REGULATORY ANALYSIS 73
5.5.2.1 North America 73
5.5.2.2 Europe 73
5.5.2.3 Asia Pacific 74
5.5.2.4 Latin America 75
5.5.2.5 Middle East & Africa 75
5.6 PRICING ANALYSIS 75
5.6.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER 76
5.6.2 INDICATIVE PRICING ANALYSIS, BY REGION 77
5.6.3 PRICING MODELS 77
5.7 VALUE CHAIN ANALYSIS 78
5.7.1 PRODUCT DESIGN & DEVELOPMENT 79
5.7.2 SYSTEM INTEGRATION & WORKFLOW CUSTOMIZATION 79
5.7.3 IMPLEMENTATION 80
5.7.4 COMPLIANCE MONITORING & AUDIT READINESS 80
5.7.5 POST-SALES SERVICES 80
5.8 ECOSYSTEM ANALYSIS 80
5.9 INVESTMENT AND FUNDING SCENARIO 83
5.10 TECHNOLOGY ANALYSIS 83
5.10.1 KEY TECHNOLOGIES 83
5.10.1.1 Document Management Systems (DMS) 83
5.10.1.2 Workflow automation and collaboration tools 84
5.10.1.3 Compliance and regulatory tools 84
5.10.1.4 Cloud storage and security 84
5.10.2 COMPLEMENTARY TECHNOLOGIES 84
5.10.2.1 Artificial Intelligence (AI)/Machine Learning (ML) 84
5.10.2.2 Blockchain 85
5.10.2.3 Robotic Process Automation (RPA) 85
5.10.2.4 Collaboration and communication tools 85
5.10.2.5 Mobile applications 85
5.10.3 ADJACENT TECHNOLOGIES 86
5.10.3.1 CLINICAL TRIAL MANAGEMENT SYSTEMS (CTMS) 86
5.10.3.2 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT (RTSM/IWRS) 86
5.10.3.3 ELECTRONIC DATA CAPTURE (EDC) 86
5.10.3.4 ECONSENT PLATFORMS 86
5.10.3.5 ESOURCE/REMOTE SOURCE DATA CAPTURE 86
5.11 PATENT ANALYSIS 87
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 89
5.13 CASE STUDY ANALYSIS 90
5.13.1 CASE STUDY 1: ENHANCED CLINICAL EFFICIENCY AND INSPECTION READINESS THROUGH VEEVA ETMF AND CTMS 90
5.13.2 CASE STUDY 2: STREAMLINED CLINICAL TRIAL OPERATIONS WITH ORACLE SIEBEL CTMS 90
5.13.3 CASE STUDY 3: TRANSITION TOWARD ELECTRONIC TMF FOR INSPECTION READINESS 91
5.14 PORTER’S FIVE FORCES ANALYSIS 91
5.14.1 BARGAINING POWER OF SUPPLIERS 93
5.14.2 BARGAINING POWER OF BUYERS 93
5.14.3 THREAT OF NEW ENTRANTS 93
5.14.4 THREAT OF SUBSTITUTES 93
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 93
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 94
5.15.2 BUYING CRITERIA 95
5.16 UNMET NEEDS ANALYSIS 95
5.16.1 CURRENT UNMET NEEDS 95
5.16.2 END-USER EXPECTATIONS 96
5.17 BUSINESS MODELS 98
5.17.1 SUBSCRIPTION-BASED (SAAS) MODEL 98
5.17.2 LICENSING MODEL 98
5.17.3 PAY-PER-USE MODEL 98
5.17.4 FREEMIUM MODEL 98
5.17.5 HYBRID MODEL 98
5.18 IMPACT OF AI/GEN AI ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 98
5.18.1 INTRODUCTION 98
5.18.2 MARKET POTENTIAL OF AI/GEN AI ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 99
5.18.3 CASE STUDY RELATED TO AI/GEN AI IMPLEMENTATION 100
5.18.3.1 AI-powered eTMF automation for CRO document processing 100
5.18.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 101
5.18.4.1 Clinical trial services 101
5.18.4.2 eClinical solutions 101
5.18.4.3 AI in clinical trials 102
5.18.5 USER READINESS AND IMPACT ASSESSMENT 102
5.18.5.1 User readiness 102
5.18.5.1.1 User A: Pharmaceutical & Biotechnology Companies 102
5.18.5.1.2 User B: Contract Research Organizations (CROs) 102
5.18.5.2 Impact assessment 103
5.18.5.2.1 User A: Pharmaceutical & Biotechnology Companies 103
5.18.5.2.2 User B: Contract Research Organizations (CROs) 103
5.19 IMPACT OF 2025 US TARIFFS ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 104
5.19.1 INTRODUCTION 104
5.19.2 KEY TARIFF RATES 104
5.19.3 PRICE IMPACT ANALYSIS 105
5.19.4 IMPACT ON COUNTRY/REGION 105
5.19.4.1 US 105
5.19.4.2 Europe 106
5.19.4.3 Asia Pacific 106
5.19.5 IMPACT ON END-USE INDUSTRIES 106
5.19.5.1 Pharmaceutical & biotechnology companies 106
5.19.5.2 Contract Research Organizations (CROs) 106
6 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING 107
6.1 INTRODUCTION 108
6.2 SOFTWARE 108
6.2.1 STANDALONE ETMF SOFTWARE 110
6.2.1.1 Easy scalability, quick implementation timelines, and reduced IT infrastructure requirements to drive market 110
6.2.2 INTEGRATED ETMF SOFTWARE 110
6.2.2.1 Shift toward unified eClinical ecosystems, cloud-based platforms, and advanced analytics capabilities to propel market 110
6.3 SERVICES 111
6.3.1 RISING COMPLEXITY OF GLOBAL AND DECENTRALIZED TRIALS TO EXPEDITE GROWTH 111
7 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS, BY FUNCTIONALITY 113
7.1 INTRODUCTION 114
7.2 DOCUMENT MANAGEMENT 114
7.2.1 NEED FOR ADVANCED DOCUMENT MANAGEMENT AND ENHANCED OPERATIONAL TRANSPARENCY TO BOLSTER GROWTH 114
7.3 WORKFLOW & COLLABORATION TOOLS 115
7.3.1 ABILITY TO OFFER STRUCTURED, LARGE-SCALE INFORMATION ON HEALTHCARE SERVICES, UTILIZATION PATTERNS, AND ASSOCIATED COSTS TO BOOST MARKET 115
7.4 COMPLIANCE & AUDIT MANAGEMENT 116
7.4.1 EXPANDING COMPLEXITY OF MULTI-SITE AND HYBRID CLINICAL TRIALS TO CONTRIBUTE TO GROWTH 116
7.5 ANALYTICS & REPORTING 118
7.5.1 INCREASING SHIFT TOWARD DATA-DRIVEN QUALITY MANAGEMENT TO STIMULATE GROWTH 118
7.6 INTEGRATION WITH OTHER ECLINICAL SYSTEMS 119
7.6.1 GROWING ADOPTION OF CLOUD-BASED AND API-ENABLED PLATFORMS TO PROPEL MARKET 119
8 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT 121
8.1 INTRODUCTION 122
8.2 CLOUD-BASED DEPLOYMENT 122
8.2.1 RISE OF DECENTRALIZED AND HYBRID CLINICAL TRIAL MODELS TO PROMOTE GROWTH 122
8.3 ON-PREMISES DEPLOYMENT 123
8.3.1 NEED FOR HIGHLY CUSTOMIZED CONFIGURATIONS AND INTEGRATION WITH EXISTING LEGACY SYSTEMS TO AID GROWTH 123
9 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA 125
9.1 INTRODUCTION 126
9.2 ONCOLOGY 126
9.2.1 INCREASING SHIFT TOWARD DECENTRALIZED AND HYBRID ONCOLOGY TRIALS TO FACILITATE GROWTH 126
9.3 CARDIOVASCULAR DISEASES 127
9.3.1 SURGE IN TRIAL ACTIVITY TO CONTRIBUTE TO GROWTH 127
9.4 RESPIRATORY DISEASES 129
9.4.1 GROWING EMPHASIS ON DEVELOPING NOVEL BIOLOGICS, INHALATION THERAPIES, VACCINES, AND PRECISION MEDICINE APPROACHES TO BOOST MARKET 129
9.5 GASTROINTESTINAL DISORDERS 130
9.5.1 RISING GLOBAL BURDEN OF GASTROINTESTINAL DISORDERS TO AUGMENT GROWTH 130
9.6 NEUROLOGICAL DISORDERS 131
9.6.1 RISE IN NEUROLOGICAL RESEARCH ACTIVITY TO STIMULATE GROWTH 131
9.7 OTHER THERAPEUTIC AREAS 132
10 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE 134
10.1 INTRODUCTION 135
10.2 PHASE I 135
10.2.1 GROWING EARLY-STAGE OUTSOURCING TO DRIVE MARKET 135
10.3 PHASE II 136
10.3.1 INCREASED STUDY ENDPOINTS AND COMPLEX PROTOCOL REQUIREMENTS TO EXPEDITE GROWTH 136
10.4 PHASE III 137
10.4.1 NEED TO ENSURE GLOBAL COMPLIANCE AND MAINTAIN END-TO-END DOCUMENT LIFECYCLE TO BOOST MARKET 137
10.5 PHASE IV 138
10.5.1 INCREASING EMPHASIS ON REAL-WORLD EVIDENCE GENERATION AND PHARMACOVIGILANCE TO SUPPORT GROWTH 138
11 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER 140
11.1 INTRODUCTION 141
11.2 PHARMACEUTICAL & BIOTECH COMPANIES 141
11.2.1 RISING REGULATORY SCRUTINY TO ENCOURAGE GROWTH 141
11.3 MEDICAL DEVICE COMPANIES 142
11.3.1 GROWING EMPHASIS ON IMPROVED PATIENT SAFETY OUTCOMES AND AUTOMATED QUALITY CHECKS TO BOOST MARKET 142
11.4 CONTRACT RESEARCH ORGANIZATIONS (CROS) 144
11.4.1 INCREASING FINANCIAL PRESSURE TO CONTROL RISING HEALTHCARE COSTS AND IMPROVE RETURN ON INVESTMENT TO SPUR GROWTH 144
11.5 ACADEMIC & HEALTHCARE RESEARCH INSTITUTIONS 145
11.5.1 NEED FOR DATA INTEGRITY, ACCURATE AUDIT TRAILS, AND CONSISTENT DOCUMENTATION PRACTICES TO FUEL MARKET 145
11.6 GOVERNMENT & NON-PROFIT ORGANIZATIONS 146
11.6.1 INCREASING EMPHASIS ON REGULATORY COMPLIANCE, DATA TRANSPARENCY, AND EFFICIENT RESOURCE UTILIZATION TO DRIVE MARKET 146
12 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY REGION 148
12.1 INTRODUCTION 149
12.2 NORTH AMERICA 150
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 151
12.2.2 US 155
12.2.2.1 Robust clinical research ecosystem and regulatory frameworks to aid growth 155
12.2.3 CANADA 159
12.2.3.1 Growing emphasis on compliance and digital clinical operations to drive market 159
12.3 EUROPE 162
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 163
12.3.2 GERMANY 166
12.3.2.1 Increasing transition toward digital documentation and regulatory harmonization to fuel market 166
12.3.3 FRANCE 170
12.3.3.1 Expanding clinical research infrastructure to contribute to growth 170
12.3.4 UK 173
12.3.4.1 Ongoing regulatory transition to expedite growth 173
12.3.5 ITALY 177
12.3.5.1 Fragmented digital infrastructure to limit growth 177
12.3.6 SPAIN 180
12.3.6.1 Growing clinical trial volume and continued investment in digital research infrastructure to boost market 180
12.3.7 REST OF EUROPE 184
12.4 ASIA PACIFIC 188
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 188
12.4.2 CHINA 192
12.4.2.1 Growing shift toward global compliance frameworks to fuel market 192
12.4.3 JAPAN 196
12.4.3.1 Rising demand for eTMF systems amid digital trial transformation to boost market 196
12.4.4 INDIA 199
12.4.4.1 Rising number of eTMF-management certification programs to promote growth 199
12.4.5 SOUTH KOREA 203
12.4.5.1 Continued support for biopharmaceutical innovations to drive market 203
12.4.6 AUSTRALIA 206
12.4.6.1 Increased digital health and clinical research modernization initiatives to bolster growth 206
12.4.7 REST OF ASIA PACIFIC 210
12.5 LATIN AMERICA 213
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 214
12.5.2 BRAZIL 218
12.5.2.1 Growing participation in global multicenter clinical trials to fuel market 218
12.5.3 MEXICO 221
12.5.3.1 Growing number of research-active hospitals to fuel market 221
12.5.4 REST OF LATIN AMERICA 225
12.6 MIDDLE EAST & AFRICA 228
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 229
12.6.2 GCC COUNTRIES 233
12.6.2.1 Saudi Arabia 236
12.6.2.1.1 Growing emphasis on transparency, quality assurance, and digital oversight to propel market 236
12.6.2.2 UAE 240
12.6.2.2.1 Favorable digital health transformation to aid growth 240
12.6.2.3 Rest of GCC countries 243
12.6.3 REST OF MIDDLE EAST & AFRICA 247
13 COMPETITIVE LANDSCAPE 252
13.1 OVERVIEW 252
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 252
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 252
13.3 REVENUE SHARE ANALYSIS, 2020–2024 254
13.4 MARKET SHARE ANALYSIS, 2024 255
13.5 BRAND/SOFTWARE COMPARISON 257
13.6 COMPANY VALUATION AND FINANCIAL METRICS 258
13.6.1 COMPANY VALUATION 258
13.6.2 FINANCIAL METRICS 258
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 259
13.7.1 STARS 259
13.7.2 EMERGING LEADERS 259
13.7.3 PERVASIVE PLAYERS 260
13.7.4 PARTICIPANTS 260
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 261
13.7.5.1 Company footprint 261
13.7.5.2 Region footprint 262
13.7.5.3 Offering footprint 263
13.7.5.4 Functionality footprint 264
13.7.5.5 End-user footprint 265
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 266
13.8.1 PROGRESSIVE COMPANIES 266
13.8.2 RESPONSIVE COMPANIES 266
13.8.3 DYNAMIC COMPANIES 266
13.8.4 STARTING BLOCKS 266
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 268
13.8.5.1 Detailed list of key startups/SMEs 268
13.8.5.2 Competitive benchmarking of startups/SMEs 268
13.9 COMPETITIVE SCENARIO 269
13.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS 269
13.9.2 DEALS 270
13.9.3 OTHER DEVELOPMENTS 271
14 COMPANY PROFILES 272
14.1 KEY PLAYERS 272
14.1.1 VEEVA SYSTEMS 272
14.1.1.1 Business overview 272
14.1.1.2 Products offered 273
14.1.1.3 Recent developments 274
14.1.1.3.1 Product launches and enhancements 274
14.1.1.3.2 Deals 274
14.1.1.4 MnM view 275
14.1.1.4.1 Right to win 275
14.1.1.4.2 Strategic choices 275
14.1.1.4.3 Weaknesses and competitive threats 275
14.1.2 ORACLE 276
14.1.2.1 Business overview 276
14.1.2.2 Products offered 277
14.1.2.3 Recent developments 278
14.1.2.3.1 Product launches and enhancements 278
14.1.2.3.2 Deals 278
14.1.2.4 MnM view 278
14.1.2.4.1 Right to win 278
14.1.2.4.2 Strategic choices 278
14.1.2.4.3 Weaknesses and competitive threats 279
14.1.3 IQVIA 280
14.1.3.1 Business overview 280
14.1.3.2 Products offered 281
14.1.3.3 Recent developments 282
14.1.3.3.1 Product launches and enhancements 282
14.1.3.3.2 Deals 283
14.1.3.4 MnM view 283
14.1.3.4.1 Right to win 283
14.1.3.4.2 Strategic choices 283
14.1.3.4.3 Weaknesses and competitive threats 284
14.1.4 MEDIDATA (DASSAULT SYSTÈMES) 285
14.1.4.1 Business overview 285
14.1.4.2 Products offered 286
14.1.4.3 Recent developments 287
14.1.4.3.1 Product launches and enhancements 287
14.1.4.3.2 Deals 287
14.1.4.4 MnM view 288
14.1.4.4.1 Right to win 288
14.1.4.4.2 Strategic choices 288
14.1.4.4.3 Weaknesses and competitive threats 288
14.1.5 TRANSPERFECT 289
14.1.5.1 Business overview 289
14.1.5.2 Products offered 289
14.1.5.3 Recent developments 290
14.1.5.3.1 Product launches and enhancements 290
14.1.5.3.2 Deals 290
14.1.5.4 MnM view 291
14.1.5.4.1 Right to win 291
14.1.5.4.2 Strategic choices 291
14.1.5.4.3 Weaknesses and competitive threats 291
14.1.6 PHLEXGLOBAL (CENCORA, INC.) 292
14.1.6.1 Business overview 292
14.1.6.2 Products offered 293
14.1.6.3 Recent developments 294
14.1.6.3.1 Product launches and enhancements 294
14.1.6.3.2 Deals 295
14.1.7 ARISGLOBAL 296
14.1.7.1 Business overview 296
14.1.7.2 Products offered 296
14.1.7.3 Recent developments 297
14.1.7.3.1 Deals 297
14.1.8 MASTERCONTROL SOLUTIONS, INC. 298
14.1.8.1 Business overview 298
14.1.8.2 Products offered 298
14.1.8.3 Recent developments 299
14.1.8.3.1 Deals 299
14.1.8.3.2 Other developments 299
14.1.9 ENNOV 300
14.1.9.1 Business overview 300
14.1.9.2 Products offered 301
14.1.9.3 Recent developments 301
14.1.9.3.1 Product launches and enhancements 301
14.1.9.3.2 Deals 302
14.1.10 MONTRIUM INC. 303
14.1.10.1 Business overview 303
14.1.10.2 Products offered 303
14.1.10.3 Recent developments 304
14.1.10.3.1 Product launches and enhancements 304
14.1.10.3.2 Deals 304
14.1.11 EXTEDO 305
14.1.11.1 Business overview 305
14.1.11.2 Products offered 306
14.1.11.3 Recent developments 307
14.1.11.3.1 Product launches and enhancements 307
14.1.11.3.2 Deals 307
14.1.12 SURECLINICAL INC. 308
14.1.12.1 Business overview 308
14.1.12.2 Products offered 308
14.1.12.3 Recent developments 309
14.1.12.3.1 Deals 309
14.1.13 FLORENCE HEALTHCARE 310
14.1.13.1 Business overview 310
14.1.13.2 Products offered 310
14.1.13.3 Recent developments 311
14.1.13.3.1 Product launches and enhancements 311
14.1.13.3.2 Deals 311
14.1.14 EGNYTE, INC. 312
14.1.14.1 Business overview 312
14.1.14.2 Products offered 312
14.1.14.3 Recent developments 313
14.1.14.3.1 Product launches and enhancements 313
14.1.14.3.2 Deals 313
14.1.14.3.3 Other developments 314
14.1.15 CLOUDBYZ 315
14.1.15.1 Business overview 315
14.1.15.2 Products offered 315
14.1.15.3 Recent developments 316
14.1.15.3.1 Deals 316
14.1.16 MYCLIN CLINICAL RESEARCH LLC 317
14.1.16.1 Business overview 317
14.1.16.2 Products offered 317
14.1.17 OCTALSOFT 318
14.1.17.1 Business overview 318
14.1.17.2 Products offered 318
14.1.18 CRUCIAL DATA SOLUTIONS 319
14.1.18.1 Business overview 319
14.1.18.2 Products offered 319
14.1.18.3 Recent developments 320
14.1.18.3.1 Product launches and enhancements 320
14.1.18.3.2 Deals 320
14.1.19 DATARIVER S.R.L. 321
14.1.19.1 Business overview 321
14.1.19.2 Products offered 321
14.1.20 AUREA, INC. 322
14.1.20.1 Business overview 322
14.1.20.2 Products offered 322
14.2 OTHER PLAYERS 323
14.2.1 AGATHA INC. 323
14.2.2 EVIDENTIQ 324
14.2.3 CLINION 325
14.2.4 ANJU SOFTWARE 326
14.2.5 CLINEVO TECHNOLOGIES 327
15 APPENDIX 328
15.1 DISCUSSION GUIDE 328
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 333
15.3 CUSTOMIZATION OPTIONS 335
15.4 RELATED REPORTS 335
15.5 AUTHOR DETAILS 336
LIST OF TABLES
TABLE 1 RISK ASSESSMENT: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 48
TABLE 2 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 60
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 7 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 8 REGULATORY SCENARIO OF NORTH AMERICA 73
TABLE 9 REGULATORY SCENARIO OF EUROPE 73
TABLE 10 REGULATORY SCENARIO OF ASIA PACIFIC 74
TABLE 11 REGULATORY SCENARIO OF LATIN AMERICA 75
TABLE 12 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 75
TABLE 13 INDICATIVE PRICE FOR ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS, BY KEY PLAYER, 2024 76
TABLE 14 INDICATIVE PRICE FOR ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS,
BY REGION, 2024 77
TABLE 15 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 82
TABLE 16 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, 2025 87
TABLE 17 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: LIST OF PATENTS/PATENT APPLICATIONS 88
TABLE 18 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 89
TABLE 19 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: PORTER’S FIVE FORCES ANALYSIS 92
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 94
TABLE 21 KEY BUYING CRITERIA FOR END USERS 95
TABLE 22 UNMET NEEDS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 96
TABLE 23 END-USER EXPECTATIONS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 97
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 104
TABLE 25 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 108
TABLE 26 MAJOR ETMF SOFTWARE OFFERINGS BY KEY PLAYERS IN MARKET 109
TABLE 27 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE,
BY TYPE, 2023–2030 (USD MILLION) 109
TABLE 28 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE,
BY REGION, 2023–2030 (USD MILLION) 109
TABLE 29 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR STANDALONE ETMF SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 30 ELECTRONIC TRIAL MASTERFILE (ETMF) SYSTEMS MARKET FOR INTEGRATED ETMF SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 31 MAJOR ETMF SERVICE OFFERINGS BY KEY PLAYERS IN MARKET 112
TABLE 32 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SERVICES,
BY REGION, 2023–2030 (USD MILLION) 112
TABLE 33 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 114
TABLE 34 MAJOR DOCUMENT MANAGEMENT OFFERINGS BY KEY PLAYERS 115
TABLE 35 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR DOCUMENT MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 36 MAJOR WORKFLOW & COLLABORATION TOOL OFFERINGS BY KEY PLAYERS IN MARKET 116
TABLE 37 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR WORKFLOW & COLLABORATION TOOLS, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 38 MAJOR COMPLIANCE & AUDIT MANAGEMENT OFFERINGS BY KEY PLAYERS 117
TABLE 39 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR COMPLIANCE & AUDIT MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 117
TABLE 40 MAJOR ANALYTICS AND REPORTING OFFERINGS BY KEY PLAYERS IN MARKET 118
TABLE 41 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR ANALYTICS & REPORTING, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 42 MAJOR ECLINICAL INTEGRATED SYSTEMS BY KEY PLAYERS IN MARKET 120
TABLE 43 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR INTEGRATION WITH OTHER ECLINICAL SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 44 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 122
TABLE 45 MAJOR CLOUD-BASED DEPLOYMENT OFFERINGS BY KEY PLAYERS IN MARKET 123
TABLE 46 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR CLOUD-BASED DEPLOYMENT, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 47 MAJOR ON-PREMISES DEPLOYMENT OFFERINGS BY KEY PLAYERS IN MARKET 124
TABLE 48 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR ON-PREMISES DEPLOYMENT, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 49 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 126
TABLE 50 MAJOR ETMF SYSTEMS FOR ONCOLOGY BY KEY PLAYERS IN MARKET 127
TABLE 51 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR ONCOLOGY,
BY REGION, 2023–2030 (USD MILLION) 127
TABLE 52 MAJOR ETMF SYSTEMS FOR CARDIOVASCULAR DISEASE BY KEY PLAYERS IN MARKET 128
TABLE 53 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 128
TABLE 54 MAJOR ETMF SYSTEMS FOR RESPIRATORY DISEASES BY KEY PLAYERS IN MARKET 129
TABLE 55 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 56 MAJOR ETMF SYSTEMS FOR GASTROINTESTINAL DISORDERS BY KEY PLAYERS IN MARKET 130
TABLE 57 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 58 MAJOR ETMF SYSTEMS FOR NEUROLOGICAL DISORDERS BY KEY PLAYERS IN MARKET 132
TABLE 59 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 60 MAJOR ETMF SYSTEMS FOR OTHER THERAPEUTIC AREAS BY KEY PLAYERS IN MARKET 133
TABLE 61 ELECTRONIC TRIAL MASTER FILE (ETMF) MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 133
TABLE 62 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 135
TABLE 63 MAJOR PHASE I OFFERINGS BY KEY PLAYERS IN MARKET 135
TABLE 64 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR PHASE I,
BY REGION, 2023–2030 (USD MILLION) 136
TABLE 65 MAJOR PHASE II OFFERINGS BY KEY PLAYERS IN MARKET 136
TABLE 66 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR PHASE II,
BY REGION, 2023–2030 (USD MILLION) 137
TABLE 67 MAJOR PHASE III OFFERINGS BY KEY PLAYERS IN MARKET 138
TABLE 68 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR PHASE III,
BY REGION, 2023–2030 (USD MILLION) 138
TABLE 69 MAJOR PHASE IV OFFERINGS BY KEY PLAYERS IN MARKET 139
TABLE 70 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR PHASE IV,
BY REGION, 2023–2030 (USD MILLION) 139
TABLE 71 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 141
TABLE 72 MAJOR ETMF SYSTEMS FOR PHARMACEUTICAL & BIOTECH COMPANIES BY KEY PLAYERS IN MARKET 142
TABLE 73 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 74 MAJOR ETMF SYSTEMS FOR MEDICAL DEVICE COMPANIES BY KEY PLAYERS IN MARKET 143
TABLE 75 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023–2030 (USD MILLION) 143
TABLE 76 MAJOR ETMF SYSTEMS FOR CONTRACT RESEARCH ORGANIZATIONS BY KEY PLAYERS IN MARKET 144
TABLE 77 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION) 145
TABLE 78 MAJOR ETMF SYSTEMS FOR ACADEMIC & HEALTHCARE RESEARCH INSTITUTIONS BY KEY PLAYERS IN MARKET 146
TABLE 79 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR ACADEMIC & HEALTHCARE RESEARCH INSTITUTIONS, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 80 MAJOR ETMF SYSTEMS FOR GOVERNMENT & NON-PROFIT ORGANIZATIONS BY KEY PLAYERS IN MARKET 147
TABLE 81 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR GOVERNMENT & NON-PROFIT ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 82 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 83 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 84 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 152
TABLE 85 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 86 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 153
TABLE 87 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 153
TABLE 88 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 154
TABLE 89 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY TRIAL PHASE, 2023–2030 (USD MILLION) 154
TABLE 90 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
BY END USER, 2023–2030 (USD MILLION) 155
TABLE 91 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 156
TABLE 92 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 93 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 157
TABLE 94 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 157
TABLE 95 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 158
TABLE 96 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 158
TABLE 97 US: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 159
TABLE 98 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 160
TABLE 99 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 100 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 160
TABLE 101 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 161
TABLE 102 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 161
TABLE 103 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET BY TRIAL PHASE, 2023–2030 (USD MILLION) 162
TABLE 104 CANADA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET BY END USER, 2023–2030 (USD MILLION) 162
TABLE 105 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 106 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 164
TABLE 107 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 108 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 164
TABLE 109 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 165
TABLE 110 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 165
TABLE 111 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 166
TABLE 112 EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 166
TABLE 113 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 167
TABLE 114 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 115 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 168
TABLE 116 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 168
TABLE 117 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 169
TABLE 118 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 169
TABLE 119 GERMANY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 170
TABLE 120 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 171
TABLE 121 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 122 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 171
TABLE 123 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 172
TABLE 124 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 172
TABLE 125 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 173
TABLE 126 FRANCE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 173
TABLE 127 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 174
TABLE 128 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 129 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 175
TABLE 130 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 175
TABLE 131 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 176
TABLE 132 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 176
TABLE 133 UK: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 177
TABLE 134 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 178
TABLE 135 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 136 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 178
TABLE 137 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 179
TABLE 138 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 179
TABLE 139 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 180
TABLE 140 ITALY: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 180
TABLE 141 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 181
TABLE 142 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 143 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 182
TABLE 144 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 182
TABLE 145 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 183
TABLE 146 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 183
TABLE 147 SPAIN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 184
TABLE 148 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 185
TABLE 149 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 150 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 185
TABLE 151 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 186
TABLE 152 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 186
TABLE 153 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY TRIAL PHASE, 2023–2030 (USD MILLION) 187
TABLE 154 REST OF EUROPE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY END USER, 2023–2030 (USD MILLION) 187
TABLE 155 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 156 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 190
TABLE 157 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 158 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 190
TABLE 159 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 191
TABLE 160 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 191
TABLE 161 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY TRIAL PHASE, 2023–2030 (USD MILLION) 192
TABLE 162 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY END USER, 2023–2030 (USD MILLION) 192
TABLE 163 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 193
TABLE 164 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 165 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 194
TABLE 166 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 194
TABLE 167 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 195
TABLE 168 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 195
TABLE 169 CHINA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 196
TABLE 170 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 197
TABLE 171 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 172 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 197
TABLE 173 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 198
TABLE 174 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 198
TABLE 175 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 199
TABLE 176 JAPAN: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 199
TABLE 177 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 200
TABLE 178 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 179 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 201
TABLE 180 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
BY DEPLOYMENT, 2023–2030 (USD MILLION) 201
TABLE 181 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 202
TABLE 182 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 202
TABLE 183 INDIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 203
TABLE 184 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 204
TABLE 185 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 186 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 204
TABLE 187 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 205
TABLE 188 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 205
TABLE 189 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY TRIAL PHASE, 2023–2030 (USD MILLION) 206
TABLE 190 SOUTH KOREA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY END USER, 2023–2030 (USD MILLION) 206
TABLE 191 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 207
TABLE 192 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 193 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 208
TABLE 194 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 208
TABLE 195 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 209
TABLE 196 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 209
TABLE 197 AUSTRALIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 210
TABLE 198 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 211
TABLE 199 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 200 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 211
TABLE 201 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 212
TABLE 202 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 212
TABLE 203 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 213
TABLE 204 REST OF ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 205 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 206 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 215
TABLE 207 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 208 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 216
TABLE 209 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 216
TABLE 210 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 217
TABLE 211 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY TRIAL PHASE, 2023–2030 (USD MILLION) 217
TABLE 212 LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY END USER, 2023–2030 (USD MILLION) 218
TABLE 213 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 219
TABLE 214 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 219
TABLE 215 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 219
TABLE 216 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 220
TABLE 217 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 220
TABLE 218 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 221
TABLE 219 BRAZIL: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 221
TABLE 220 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 222
TABLE 221 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 222 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 223
TABLE 223 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
BY DEPLOYMENT, 2023–2030 (USD MILLION) 223
TABLE 224 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 224
TABLE 225 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 224
TABLE 226 MEXICO: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET BY END USER, 2023–2030 (USD MILLION) 225
TABLE 227 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 226
TABLE 228 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 226
TABLE 229 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 226
TABLE 230 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 227
TABLE 231 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 227
TABLE 232 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 228
TABLE 233 REST OF LATIN AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 228
TABLE 234 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION) 229
TABLE 235 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 230
TABLE 236 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 237 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 230
TABLE 238 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 231
TABLE 239 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 231
TABLE 240 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 232
TABLE 241 MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 232
TABLE 242 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 233
TABLE 243 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 234
TABLE 244 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 245 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 234
TABLE 246 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
BY DEPLOYMENT, 2023–2030 (USD MILLION) 235
TABLE 247 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 235
TABLE 248 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY TRIAL PHASE, 2023–2030 (USD MILLION) 236
TABLE 249 GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY END USER, 2023–2030 (USD MILLION) 236
TABLE 250 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 237
TABLE 251 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 252 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 238
TABLE 253 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 238
TABLE 254 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 239
TABLE 255 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET
BY TRIAL PHASE, 2023–2030 (USD MILLION) 239
TABLE 256 SAUDI ARABIA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY END USER, 2023–2030 (USD MILLION) 240
TABLE 257 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 241
TABLE 258 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 259 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY FUNCTIONALITY, 2023–2030 (USD MILLION) 241
TABLE 260 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY DEPLOYMENT, 2023–2030 (USD MILLION) 242
TABLE 261 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 242
TABLE 262 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 243
TABLE 263 UAE: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 243
TABLE 264 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 244
TABLE 265 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 266 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 245
TABLE 267 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 245
TABLE 268 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 246
TABLE 269 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 246
TABLE 270 REST OF GCC COUNTRIES: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 247
TABLE 271 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 248
TABLE 272 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET FOR SOFTWARE, BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 273 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2023–2030 (USD MILLION) 249
TABLE 274 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION) 249
TABLE 275 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250
TABLE 276 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2023–2030 (USD MILLION) 250
TABLE 277 REST OF MIDDLE EAST & AFRICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER, 2023–2030 (USD MILLION) 251
TABLE 278 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, JANUARY 2022–SEPTEMBER 2025 252
TABLE 279 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: DEGREE OF COMPETITION 256
TABLE 280 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: REGION FOOTPRINT 262
TABLE 281 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: OFFERING FOOTPRINT 263
TABLE 282 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: FUNCTIONALITY FOOTPRINT 264
TABLE 283 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: END-USER FOOTPRINT 265
TABLE 284 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 268
TABLE 285 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 268
TABLE 286 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022–SEPTEMBER 2025 269
TABLE 287 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: DEALS,
JANUARY 2022–SEPTEMBER 2025 270
TABLE 288 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 271
TABLE 289 VEEVA SYSTEMS: COMPANY OVERVIEW 272
TABLE 290 VEEVA SYSTEMS: PRODUCTS OFFERED 273
TABLE 291 VEEVA SYSTEMS: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 274
TABLE 292 VEEVA SYSTEMS: DEALS, JANUARY 2022–SEPTEMBER 2025 274
TABLE 293 ORACLE: COMPANY OVERVIEW 276
TABLE 294 ORACLE: PRODUCTS OFFERED 277
TABLE 295 ORACLE: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 278
TABLE 296 ORACLE: DEALS, JANUARY 2022–SEPTEMBER 2025 278
TABLE 297 IQVIA: COMPANY OVERVIEW 280
TABLE 298 IQVIA: PRODUCTS OFFERED 281
TABLE 299 IQVIA: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 282
TABLE 300 IQVIA: DEALS, JANUARY 2022–SEPTEMBER 2025 283
TABLE 301 MEDIDATA (DASSAULT SYSTÈMES): COMPANY OVERVIEW 285
TABLE 302 MEDIDATA (DASSAULT SYSTÈMES): PRODUCTS OFFERED 286
TABLE 303 MEDIDATA (DASSAULT SYSTÈMES): PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022–SEPTEMBER 2025 287
TABLE 304 MEDIDATA (DASSAULT SYSTÈMES): DEALS, JANUARY 2022–SEPTEMBER 2025 287
TABLE 305 TRANSPERFECT: COMPANY OVERVIEW 289
TABLE 306 TRANSPERFECT: PRODUCTS OFFERED 289
TABLE 307 TRANSPERFECT: PRODUCT LAUNCHES AND ENHANCEMENTS, ENHANCEMENTS JANUARY 2022–SEPTEMBER 2025 290
TABLE 308 TRANSPERFECT: DEALS, JANUARY 2022–SEPTEMBER 2025 290
TABLE 309 PHLEXGLOBAL (CENCORA, INC.): COMPANY OVERVIEW 292
TABLE 310 PHLEXGLOBAL (CENCORA, INC.): PRODUCTS OFFERED 293
TABLE 311 PHLEXGLOBAL (CENCORA, INC.): PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022–SEPTEMBER 2025 294
TABLE 312 PHLEXGLOBAL (CENCORA, INC.): DEALS, JANUARY 2022–SEPTEMBER 2025 295
TABLE 313 ARISGLOBAL: COMPANY OVERVIEW 296
TABLE 314 ARISGLOBAL: PRODUCTS OFFERED 296
TABLE 315 ARISGLOBAL: DEALS, JANUARY 2022–SEPTEMBER 2025 297
TABLE 316 MASTERCONTROL SOLUTIONS, INC.: COMPANY OVERVIEW 298
TABLE 317 MASTERCONTROL SOLUTIONS, INC.: PRODUCTS OFFERED 298
TABLE 318 MASTERCONTROL SOLUTIONS, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 299
TABLE 319 MASTERCONTROL SOLUTIONS, INC.: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 299
TABLE 320 ENNOV: COMPANY OVERVIEW 300
TABLE 321 ENNOV: PRODUCTS OFFERED 301
TABLE 322 ENNOV: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 301
TABLE 323 ENNOV: DEALS, JANUARY 2022–SEPTEMBER 2025 302
TABLE 324 MONTRIUM INC.: COMPANY OVERVIEW 303
TABLE 325 MONTRIUM INC.: PRODUCTS OFFERED 303
TABLE 326 MONTRIUM INC.: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 304
TABLE 327 MONTRIUM INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 304
TABLE 328 EXTEDO: COMPANY OVERVIEW 305
TABLE 329 EXTEDO: PRODUCTS OFFERED 306
TABLE 330 EXTEDO: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 307
TABLE 331 EXTEDO: DEALS, JANUARY 2022–SEPTEMBER 2025 307
TABLE 332 SURECLINICAL INC.: COMPANY OVERVIEW 308
TABLE 333 SURECLINICAL INC.: PRODUCTS OFFERED 308
TABLE 334 SURECLINICAL INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 309
TABLE 335 FLORENCE HEALTHCARE: COMPANY OVERVIEW 310
TABLE 336 FLORENCE HEALTHCARE: PRODUCTS OFFERED 310
TABLE 337 FLORENCE HEALTHCARE: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 311
TABLE 338 FLORENCE HEALTHCARE: DEALS, JANUARY 2022–SEPTEMBER 2025 311
TABLE 339 EGNYTE, INC.: COMPANY OVERVIEW 312
TABLE 340 EGNYTE, INC.: PRODUCTS OFFERED 312
TABLE 341 EGNYTE, INC.: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 313
TABLE 342 EGNYTE, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 313
TABLE 343 EGNYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024 314
TABLE 344 CLOUDBYZ: COMPANY OVERVIEW 315
TABLE 345 CLOUDBYZ: PRODUCTS OFFERED 315
TABLE 346 CLOUDBYZ: DEALS, JANUARY 2022–SEPTEMBER 2025 316
TABLE 347 MYCLIN CLINICAL RESEARCH LLC: COMPANY OVERVIEW 317
TABLE 348 MYCLIN CLINICAL RESEARCH LLC: PRODUCTS OFFERED 317
TABLE 349 OCTALSOFT: COMPANY OVERVIEW 318
TABLE 350 OCTALSOFT: PRODUCTS OFFERED 318
TABLE 351 CRUCIAL DATA SOLUTIONS: COMPANY OVERVIEW 319
TABLE 352 CRUCIAL DATA SOLUTIONS: PRODUCTS OFFERED 319
TABLE 353 CRUCIAL DATA SOLUTIONS: PRODUCT LAUNCHES AND ENHANCEMENTS,
JANUARY 2022–SEPTEMBER 2025 320
TABLE 354 CRUCIAL DATA SOLUTIONS: DEALS, JANUARY 2022–SEPTEMBER 2025 320
TABLE 355 DATARIVER S.R.L.: COMPANY OVERVIEW 321
TABLE 356 DATARIVER S.R.L.: PRODUCTS OFFERED 321
TABLE 357 AUREA, INC.: COMPANY OVERVIEW 322
TABLE 358 AUREA, INC.: PRODUCTS OFFERED 322
TABLE 359 AGATHA INC.: COMPANY OVERVIEW 323
TABLE 360 EVIDENTIQ: COMPANY OVERVIEW 324
TABLE 361 CLINION: COMPANY OVERVIEW 325
TABLE 362 ANJU SOFTWARE: COMPANY OVERVIEW 326
TABLE 363 CLINEVO TECHNOLOGIES: COMPANY OVERVIEW 327
LIST OF FIGURES
FIGURE 1 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET SEGMENTATION AND REGIONAL SCOPE 33
FIGURE 2 RESEARCH DESIGN 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 41
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 43
FIGURE 5 BOTTOM-UP APPROACH 44
FIGURE 6 TOP-DOWN APPROACH 44
FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS 45
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
FIGURE 9 DATA TRIANGULATION METHODOLOGY 47
FIGURE 10 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING,
2025 VS. 2030 (USD MILLION) 50
FIGURE 11 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY FUNCTIONALITY, 2025 VS. 2030 (USD MILLION) 50
FIGURE 12 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT, 2025 VS. 2030 (USD MILLION) 51
FIGURE 13 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 52
FIGURE 14 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE, 2025 VS. 2030 (USD MILLION) 52
FIGURE 15 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 53
FIGURE 16 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 54
FIGURE 17 GROWING REGULATORY REQUIREMENTS AND GOVERNMENT INITIATIVES
TO DRIVE MARKET 55
FIGURE 18 SOFTWARE SEGMENT AND US LED NORTH AMERICAN MARKET IN 2025 56
FIGURE 19 INDIA TO ACCOUNT FOR HIGHEST GROWTH DURING FORECAST PERIOD 57
FIGURE 20 ASIA PACIFIC TO HAVE HIGHEST GROWTH RATE DURING FORECAST PERIOD 57
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 58
FIGURE 22 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
FIGURE 23 CLINICAL TRIALS CONDUCTED, BY COUNTRY, 2024 61
FIGURE 24 HEALTHCARE DATA BREACHES, 2009–2025 66
FIGURE 25 INDIVIDUALS AFFECTED BY HEALTHCARE DATA BREACHES, 2009–2025 66
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 68
FIGURE 27 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: VALUE CHAIN ANALYSIS 79
FIGURE 28 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: ECOSYSTEM ANALYSIS 81
FIGURE 29 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: INVESTMENT AND FUNDING SCENARIO 83
FIGURE 30 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET (2025) 87
FIGURE 31 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: PATENT ANALYSIS, 2015–2025 88
FIGURE 32 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: PORTER’S FIVE FORCES ANALYSIS 92
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 94
FIGURE 34 KEY BUYING CRITERIA FOR END USERS 95
FIGURE 35 MARKET POTENTIAL OF AI/GEN AI ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS ACROSS INDUSTRIES 99
FIGURE 36 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 101
FIGURE 37 NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET SNAPSHOT 151
FIGURE 38 ASIA PACIFIC: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET SNAPSHOT 189
FIGURE 39 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 254
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, 2024 255
FIGURE 41 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS 257
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 258
FIGURE 43 EV/EBITDA OF KEY VENDORS 258
FIGURE 44 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: COMPANY EVALUATION MATRIX (2024) 260
FIGURE 45 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: COMPANY FOOTPRINT 261
FIGURE 46 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 267
FIGURE 47 VEEVA SYSTEMS: COMPANY SNAPSHOT (2024) 273
FIGURE 48 ORACLE: COMPANY SNAPSHOT (2024) 277
FIGURE 49 IQVIA: COMPANY SNAPSHOT (2024) 281
FIGURE 50 MEDIDATA (DASSAULT SYSTÈMES): COMPANY SNAPSHOT (2024) 286
FIGURE 51 PHLEXGLOBAL (CENCORA, INC.): COMPANY SNAPSHOT (2024) 293
FIGURE 52 EXTEDO: COMPANY SNAPSHOT (2024) 306
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11